drugset / Trial / NCT03702036
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
Summary
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Molibresib | Small molecule | 20 mg | Oral |